Ятрогенная гиперкалиемия: диагностика и лечение
Аннотация
Гиперкалиемия является угрожающим жизни электролитным нарушением. В обычных условиях она наблюдается редко, благодаря гомеостатическим механизмам, обеспечивающим поддержание нормального уровня калия в плазме крови. Среди этих механизмов особое место занимает способность почек усиленно экскретировать калий при повышении его уровня в крови. Следовательно, гиперкалиемия почти всегда связана с повреждением этого механизма. Однако при острой и хронической почечной недостаточности ее развитию может способствовать и избыточное поступление калия извне. ** Публикуется по согласованию с автором и с разрешения Oxford University Press. ** Перевод И.Г. Ким
Об авторах
С. Сиамопулос Костас
Отдел внутренней медицины. Отделение нефрологии, Университетский госпиталь, Иоаннина, Греция
Россия
Россия
Элисаф Мозес
Отдел внутренней медицины. Отделение нефрологии, Университетский госпиталь, Иоаннина, Греция
Россия
Россия
Катоподис Костас
Отдел внутренней медицины. Отделение нефрологии, Университетский госпиталь, Иоаннина, Греция
Россия
Россия
Список литературы
1. Brown R.S. Extrarenal potassium homeostasis. Kidney Int 1986; 30: 116-127.
2. Stanton B.A. Renal potassium transport: Morphological and functional adaptations. Am J Physiol 1989; 257: R989-R997.
3. Wright F.S. Renal potassium handling. Semin Nephrol 1987; 7: 174-184.
4. Rabelink T.J., Koomans Н.А., Hene’ R.J., Dorhout Mees E.J. Early and late adjustment to potassium loading in humans. Kidney Int 1990; 38: 942-947.
5. Rose B.D. Hyperkalemia In: Rose B.D., ed. Clinical Physiology of Acid-Base and Electrolyte Disorders, 4th edn. McGraw Hill, New York, 1994; 823-862.
6. Ponce S.P., Jennings A.E., Madias N.E., Harrington J.T. Drug-induced hyperkalemia. Medicine 1985; 64: 357-370.
7. DeVita M.V., Han H., Chan R., Zabetakis P.M., Gleim G.W., Michelis M.F. Drug use and the elderly in relation to changing etiologies of hyperkalemia. Geriatr Nephrol Urol 1991; 1: 41-45.
8. Rimmer J.M., Horm J.F., Gennari F.J. Hyperkalemia as a complication of drug therapy. Arch Intern Med 1987; 147: 867-869.
9. Michelis M.F. Hyperkalemia in the elderly. Am J Kidney Dis 1990; 16; 296-299.
10. Hegstad R., Brown R.D., Jiang N.-S. et al. Aging and aldosterone. Am J Med 1983; 74: 442-448.
11. Mulkerrin E., Epstein F.H., Clark B.A. Aldosterone responses to hyperkalemia in healthy elderly humans. J Am Soc Nephrol 1995; 6: 1459-1462.
12. DuBose T.D. Hyperkalemic hyperchloremic metabolic acidosis: pathophysiologic insights. Kidney Int 1997; 51: 591-602.
13. Alappan R., Perazella M.A., Buller G.K. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 1996; 124: 316-320.
14. Elisaf M., Terrovitou Ch., Tomos P., Siamopoulos К.С. Severe hyperkalaemia after co-trimoxazole administration in a patient with hyporeninaemic hypoaldosteronism. Nephrol Dial Transplant 1997; 12: 1254-1255.
15. DcFronzo R.A. Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int 1980; 17: 118-114.
16. Williams G.H. Hyporeninemic hypoaldosleronism. N Engl J Med 1986; 314; 1041-1042.
17. Choi M.J, Fernandez P.C, Patnaik A. et al. Trimethoprim-induced hyperkalemia in a patient with AIDS. N EngI J Med 1993; 328: 703-706.
18. Velazquez H., Perazella M.A., Wright F.S., Ellison D.H. Renal mechanism of trimethoprim-incluced hyperkalemia. Ann Intern Med 1993; 119: 296-301.
19. Schreiber M., Schlanger L.E., Chcn C.-B. et al. Antikaliuretic action of trimethoprim is minimized by raising urine pH. Kidney Int 1996; 49: 82-87.
20. Schreiber M., Halperin M.L. Urea excretion rate as a contributor to trimethoprim-induced hyperkalemia. Aim Intern Med 1994; 120: 166-167.
21. Reiser I.W., Chou S.-Y., Brown M.I., Porush J.G. Reversal of trimethoprim-induced antikaliuresis. Kidney Int 1996; 50: 2063-2069.
22. Zager R.A. Rhabdomyolysis and myohemoglobinuric acute renal failure. Kidney Jnt 1996; 49: 314-326.
23. Prendergast B.D., George C.F. Drug-induced rhabdomyolysis mechanisms and management. Postgrad Med J 1993; 69: 333-336.
24. Terrovitou C.T., Milionis H.J., Elisaf M.S. Acute rhabdomyolysis after bezafibrate re-exposure. Nephron (in press).
25. Demedts W., Desager Z., Belpaire F., Rinqon S., Lameire N. Life threatening hyperkalemia associated with clofibrale-induced myopathy in a CAPD patient. Perit Dial Bull 1983: 3: 15-16.
26. Textror S.C., Bravo E.L., Fouad F.M., Tarazi R.C. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril Am J Med 1982; 73:719-725.
27. Doman К., Pcrlmuttcr J.A., Muhamincdi M. et al. Life-threatening hyperkalemia associated with captopril administration. South Med J 1993; 86: 1269-1272.
28. Gorriz J.L., Garcia-Ramos J.L., Pallardo L.M. Rhabdomyolysis and acute renal failure associated with bezafibrate treatment. Nephrol Dial Transplant 1995; 10: 2371-2372.
29. Chan MK. Sustained-release bezafibrate соrrects lipid abnormalities in patients on continuous ambulatory peritoneal dialysis. Nephron 1990; 56: 56-61.
30. Van Puijenbroek E.P., DuBuf-Vcreijken P.W.G., Spooren P.F.M.J., Van Doormaal J.J. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med 1996; 240: 403-404.
31. Panuccio V., Enia G., Parlongo S., Cutrupi S., Zoccali C. Severe rhabdomyolysis induced by a retard formulation of bezafibrate in a CAPD patient. Nephron 1996; 73: 736.
32. Bcdani P.L., Perini L., Gilli P. Acute rhahdomyolysis and hemoglobin reduction after bezafibrate overdose in hyperlipidemic patients on hemodialysis. Nephron 1994: 68: 512-513.
33. Gupta P., Franco-Saenz R., Mulrow P.J. Locally generated angiotensin II in the adrenal gland regulates basal, corticotropin and potassium stimulated aldosterone secretion. Hypertension 1995; 25: 443-448.
34. Pratt J. Role of angiotensin II in potassium mediated aldosterone secretion in the dog. J Clin Invest 1982: 70: 667-672.
35. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial. Arch Intern Med 1984: 144: 1947-1953.
36. Grossman A., Eckland D., Price P. et al. Captoprii: reversible renal failure with severe hyperkalemia. Lancet 1980: 1: 712.
37. Packer M., Lee W.H. Provocation of’ hyper- and hypokalemic sudden death during treatment with and withdrawal of converting enzyme inhibition in severe chronic congestive heart failure. Am J Cardiol 1986; 57: 347-370.
38. Burnakis T.G., Mioduch H.J. Combined therapy with captopril and potassium supplementation. Arch lntern Med 1984: 144: 2371-2372.
39. Sterns R.H., Spital A. Disorders of internal potassium balance. Semin Nephrol 1987; 7: 206-222.
40. BauerJ.H. Effects of propranolol therapy on renal function and body fluid composition. Arch Intern Med 1983; 14: 927-931.
41. Lim M., Lipton R.A.F., Wolff C.B., Band D.M. Propranolol, exercise, and arterial plasma potassium. Lancet 1981; 12: 591.
42. Belhune D., McKay R. Paradoxical changes in serum-potassium during cardiopulmonary bypass in association with non-cardioselective beta blockade. Lancet 1978; 12: 380-381.
43. Lowenthal D.T., Affrime M.B., Rosenthal L., Gould A.B., Borruso J., Falkner B. Dynamic and biochemical responses to single and repeated doses clonidine during dynamic physical activity. Clin Pharmacol Ther 1982; 32: 18-24.
44. Rosenihal L.S., Lowenthal D.T., Affrime M.B., Falkner B., Gould A.B. The renin-aldosterone-potassium response to methyldopa during dynamic physical activity. Clin Phurniacul Ther 1982; 31: 264-265.
45. Castellino P., Bia M.J., DeFronzo R.A. Adrenergic modulation of potassium metabolism in uremia. Kidney Int 1990; 37: 773-798.
46. Tan S.Y., Shapiro R., Franco R. et al. Indomethacin induced prostaglandin inhibition with hyperkalemia; A reversible cause of hyporeninic hypoaldosteronism. Ann Intern Med 1979; 90: 783-785.
47. Garella S., Matarese R.A. Renal effects of prostaglandins and clinical adverse effects of non-steroidal anti-inflammatory agents. Medicine 1984; 3:165-181.
48. Zimran A., Kramer M., Plaskin M., Hershko C. Incidence of hyperkalaemia induced by indomethacin in a hospital population. Lancet 1985; 291: 107-108.
49. Phelps K.R., Oh M.S., Carroll H.J. Heparin-induced hyperkalemia. Report of a case Nephron 1980; 25: 254.
50. Sherman R.A., Ruddy M.C. Suppression of aldosterone production by low-dose heparin. Am J Nephrol 1986; 6: 165.
51. О’Kelly R., Magee F., McKenna T.F. Routine heparin therapy inhibits adrenal aldosterone production. J Clin Endocrinol Metab 1983; 56: 108-112.
52. Edes Т.Е., Sunderrajan E.V. Heparin-induced hyperkalemia. Arch Intern Med 1985; 145: 1070-1072.
53. Oster J.R., Singer I., Fishman L.M. Heparin-induced aldosterone suppresion and hyperkalemia. Am J Med 1995; 98: 575-586.
54. Gonzalez-Martin G., Diaz-Molinas M.S., Martinez A.M. et al. Heparin-induced hyperkalemia: a prospective study. Inl J Clin Pharmacol Ther Toxicol 1991; 29: 446-450.
55. Durand D., Ader J.-L., Rey J.-P. et al. Inducing hyperkalemia by converting enzyme inhibitors and heparin. Kidney Int1988; 34 [Suppl25]: S196-S197.
56. Antonipillai I., Wang Y., Horton R. Tumor necrosis factor and inlerleukin-1 may regulate renin secretion. Endocrinology 1990; 126: 273-278.
57. Canova C.R., Fischler M.P., Reinhart W.H. Effect of low-molecular-wcight heparin on serum potassium. Lancet 1997; 349: 1447-1448.
58. Wiggam M.I., Beringer T.R.O. Effect of low-molccular-weight heparin on serum concentrations of potassium. Lancet 1997; 350: 292-293.
59. Kleyman T.R., Robers С., Ling B.N. A mechanism for pentamid-ine-induced hyperkalemia: inhibition of distal nephron sodium transport. Ann Intern Med 1995; 122: 103-106.
60. Kalin M., Poretsky L., Seres D.J., Zumoff B. Hypereninemic hypoaldosteronism associated with AIDS. Am J Med 1987; 82: 1035-1038.
61. Kamel K.S., Ethier J.H., Quaggin S. et al. Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine. J Am Soc Nephrol 1991; 2: 1279-1284.
62. Bantle J.P., Nath K.A., Sutherland E.R., Najarian J.S., Ferns T.F. Effects of cyclosporine on the renin-angiotensin-aldosterone system and potassium excretion in renal transplant recipients. Arch Intern Med 1985; 145: 505-508.
63. Smith T.W. Digitalis: Mechanisms of action and clinical use. N Engl J Med 1988; 318: 358-365.
64. Lown B., Black A., Moore F.D. Digitalis, electrolytes and the surgical patient. Am J Cardiol 1960; 6: 309-311.
65. Asplund J., Edhag О., Mogensen L. et al. Four cases of massive digitalis poisoning. Acta Med Scand 1971; 189: 293-297.
66. Reza M.J., Kovick R.B., Shine K.I., Pearce M.L. Massive intravenous digoxin overdosage. N Engi J Med 1974; 291: 777-778.
Рецензия
Для цитирования:
Костас С.С., Мозес Э., Костас К. Ятрогенная гиперкалиемия: диагностика и лечение. Нефрология и диализ. 2000;2(3):176-181.
For citation:
Kostas C.S., Moses E., Kostas K. Iatrogenic hyperkalaemia - points to consider in diagnosis and management. Nephrology and Dialysis. 2000;2(3):176-181. (In Russ.)
Просмотров:
1
Послать статью по эл. почте 